Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of October 31, 2011:
- Total issued Ordinary shares: 5,571,832,621 (25p each).
- Treasury shares held: 509,289,248.
- Total voting rights: 5,062,543,373.
No material changes to financial performance or operational status are reported in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,062,543,373) for compliance with Financial Services Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (509,289,248) as of October 31, 2011.
- Review the Company's Form 20-F for comprehensive financial performance data, as this 6-K does not contain financial statements.